Overview
- 6 inspections across 6 sites are on record.
- 0 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2025-04-30.
At a glance
Inspections
6
Sites
6
Observations
0
Career since
Dec 2022
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| ULTRAGENYX | 30 Apr 2025 | Biologics | On file |
| ULTRAGENYX | 25 Apr 2025 | Biologics | On file |
| AUTOLUS LIMITED | 30 Apr 2024 | Biologics | On file |
| Novartis Pharma Stein AG | 20 Nov 2023 | Biologics | |
| Grifols Therapeutics LLC | 1 Sep 2023 | Biologics | On file |
Sites inspected
ULTRAGENYXWoburn, United States1 insp.
ULTRAGENYXBedford, United States1 insp.
AUTOLUS LIMITEDStevenage, United Kingdom1 insp.
Novartis Pharma Stein AGStein Ag, Switzerland1 insp.
Grifols Therapeutics LLCClayton, United States1 insp.
Co-investigators
Investigators who share inspections with this person.
Timothy Kamaldinov2 shared
Jacob L Bitterman2 shared
Massoud Motamed2 shared
Jessica Chery2 shared
Kathleen R Jones2 shared
Andrew E Timmons1 shared
Yonggang Wang1 shared
Bradley J Dworak1 shared
Emmanuel Adu-Gyamfi1 shared
Andrew W Harmon1 shared
Full investigator report
Get the verbatim findings behind Kula N Jha's inspection record
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site